<DOC>
	<DOCNO>NCT02393300</DOCNO>
	<brief_summary>Previous study cardiovascular orthopedic study show tranexamic acid ( TXA ) reduce blood loss post-operative blood transfusion rate largely without major complication . In addition , many meta-analyses confirm result . However , little information comparison among different route TXA administration TKA . Therefore , study design determine administration route TXA effective safety .</brief_summary>
	<brief_title>Comparison Topical Versus Intravenous Tranexamic Acid TKA</brief_title>
	<detailed_description>Objectives : To assess efficacy safety two different apply route . Patients project randomly divide three group , one group blank group rest two receive either topical intravenous form tranexamic acid unilateral TKA ( total knee arthroplasty ) .The total blood loss ( TBL ) calculate primary outcome efficacy Deep Vein Thrombosis、Pulmonary Embolism、Acute Myocardial Infarction 、 Acute Kidney Infarction Cerebral Infarction event record assess safety tranexamic acid six-week follow-up patient . All surgery general anesthesia , direct lateral approach cementless prosthesis.For patient , drain tube clamp close completely 2 hour ; clamp fully open .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Exsanguination</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>1 . Consented join project . 2 . Adult patient ( great 18 year old ) 3 . Patients schedule primary unilateral knee arthroplasty 1 . Patients refuse sign Inform Consent 2 . Had allergy TXA . 3 . Using anticoagulant drug within week . 4 . Coagulopathy ( preoperative platelet count &lt; 150,000/mm3 , International Sensitivity Index（INR） &gt; 1.4 , prolong Activated Partial Thromboplastin Time，Prothrombin Time ，or thrombin time &gt; 1.4 time longer normal . 5 . Breastfeeding 6 . Major comorbidities : Severe ischemic heart disease ( class III IV New York Heart Association ) ; sleep apnea syndrome ; renal dysfunction ( glomerular filtration rate &lt; 60 ) ; hepatic disfunction ( glutamicpyruvic transaminase &gt; 80 glutamic oxalacetic transaminase &gt; 80 ) .Retinopathy ( disturbance color vision ) . 9.History thromboembolic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>tranexamic acid</keyword>
	<keyword>blood loss</keyword>
	<keyword>topical administration</keyword>
	<keyword>intravenous administration</keyword>
</DOC>